10-Q: VivoSim Labs Faces Going Concern Amid Business Pivot

VivoSim Labs, Inc. reports a reduced net loss but faces substantial doubt about its ability to continue as a going concern, despite a strategic shift to 3D human tissue models and promising liver toxicology platform results.

Summary

• VivoSim Labs, Inc. has transitioned its business model from a clinical-stage biotechnology company to a pharmaceutical and biotechnology services company, focusing on testing drugs in 3D human tissue models of liver and intestine.
• The company reported a net loss of $2.843 million for the three months ended June 30, 2025, an improvement from a net loss of $3.344 million in the same period last year.
• Total revenues for the quarter were $37,000, primarily from royalty revenue, a slight decrease from $39,000 in the prior year, as product revenue ceased with the end of the Mosaic division's operations.
• Research and development expenses decreased by 29% to $1.001 million, and selling, general and administrative expenses decreased by 3% to $1.951 million.
• Cash and cash equivalents decreased to $9.055 million as of June 30, 2025, from $11.312 million on March 31, 2025.
• Net cash used in operating activities increased to $3.940 million for the quarter, up from $2.983 million in the prior year period, primarily due to the timing of R&D projects and related payables.
• The company's liver toxicology platform demonstrated a 'best-in-class predictive power' with 87.5% sensitivity and 100% specificity in identifying liver-toxic drugs, as presented at the May 2025 Digestive Disease Week scientific conference.
• VivoSim Labs sold its FXR program in March 2025 for $10.0 million, including $9.0 million paid at closing and $1.0 million held in escrow, with potential future milestones of up to $50.0 million.
• The company continues to advance its Preclinical IBD Program, aiming for an Investigational New Drug (IND) Application with the FDA by December 2026.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least one year, citing the need for substantial additional funding.
• The company has $140.1 million unallocated under its 2024 Shelf registration and $3.1 million available for future offerings through its At-The-Market (ATM) program, but is limited by its public float being less than $75.0 million.

Sentiment

Score: 3

Explanation: The sentiment is low due to the explicit 'going concern' warning, significant cash burn, and the need for substantial additional funding. While the strategic pivot and promising platform data offer long-term potential, the immediate financial viability is highly uncertain, outweighing the positive operational improvements in reducing net loss and expenses.

Positives

• Net loss decreased to $2.843 million for the three months ended June 30, 2025, from $3.344 million in the prior year, indicating improved operational efficiency in reducing losses.
• Research and development expenses significantly decreased by 29% to $1.001 million, reflecting a reduction in personnel and materials costs.
• Selling, general and administrative expenses also saw a 3% decrease to $1.951 million, driven by lower personnel-related expenses.
• The company's liver toxicology platform demonstrated 'best-in-class predictive power' with 87.5% sensitivity and 100% specificity, a 'world's best' according to the company, which could attract pharmaceutical partners.
• The sale of the FXR program for $10.0 million, with potential for up to $50.0 million in future milestone payments, provides a significant non-dilutive funding source and strategic focus.
• The FDA's April 10, 2025 announcement favoring non-animal New Approach Methodologies (NAM) is expected to accelerate the adoption of human tissue models, aligning with VivoSim's new business focus.
• The Preclinical IBD Program is advancing, with a goal of an IND Application by December 2026, indicating continued internal drug discovery efforts.

Negatives

• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least one year, highlighting significant financial instability.
• Cash and cash equivalents decreased by $2.257 million from March 31, 2025, to June 30, 2025, indicating a rapid cash burn.
• Net cash used in operating activities increased to $3.940 million for the quarter, up from $2.983 million in the prior year, showing an increased operational cash outflow.
• The company's accumulated deficit grew to $345.0 million as of June 30, 2025, reflecting a history of significant operating losses.
• Total revenues remain very low at $37,000, indicating that the new services business has not yet generated significant income.
• The company's public float is less than $75.0 million, limiting its ability to raise capital through primary public offerings to one-third of its public float in any twelve-month period.
• The company faces a legal complaint from H.C. Wainwright & Co., LLC seeking compensatory and consequential damages, with an accrual of $0.6 million for loss contingencies.

Risks

• Substantial additional operating losses are expected as services and R&D activities proceed, with no certainty of achieving profitability.
• The business strategy of using 3D human tissue models for drug discovery and development is new and unproven, potentially leading to unforeseen technical complications or delays.
• The company requires a constant, steady, reliable supply of human cells, and failure to obtain them at cost-effective prices would harm the business.
• Substantial additional funding is required, and raising capital through equity or convertible debt would cause dilution to existing stockholders or impose restrictive covenants.
• Clinical drug development is a lengthy, expensive, and uncertain process, and results of earlier studies may not be predictive of future outcomes.
• The near and long-term viability of the services platform and R&D efforts depend on successfully establishing strategic relationships, which is difficult and time-consuming.
• Unstable market and economic conditions may adversely affect the business, financial condition, and share price, including the ability to raise capital.
• Changes in government funding for regulatory agencies like the FDA and SEC could hinder their ability to review submissions, delaying product development or commercialization.
• Failure to maintain Nasdaq listing requirements, such as minimum bid price or stockholders' equity, could lead to delisting, reducing stock liquidity and ability to raise capital.
• The anticipated benefits of the FXR program sale, particularly the $50.0 million in milestone payments, may not be fully realized if milestones are not achieved.
• Conflicts of interest may arise with Viscient Biosciences, Inc., a related party where the Executive Chairman also serves as CEO, potentially impacting business dealings and intellectual property ownership.
• The company may not be successful in acquiring or in-licensing necessary rights to key technologies for its liver toxicology screening and research services platform.
• Inability to adequately prevent disclosure of trade secrets and other proprietary information could adversely affect competitive position.
• The company may be subject to security breaches or other cybersecurity incidents, compromising information and exposing it to liability.
• Compliance with global privacy and data security requirements is evolving and could result in additional costs, liabilities, or inhibit data processing, with potential for significant fines.
• Patents covering products could be found invalid or unenforceable if challenged, or the company may be involved in expensive and time-consuming lawsuits to protect intellectual property.

Future Outlook

The company anticipates accelerated adoption of human tissue models following the FDA's April 10, 2025 announcement favoring non-animal New Approach Methodologies (NAM). It plans to offer bespoke services in investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The goal for the Preclinical IBD Program is to have a product candidate ready for an Investigational New Drug (IND) Application with the FDA by December 2026. Total operating expenses for the fiscal year ending March 31, 2026, are expected to be between $10 million and $11 million. The company will need substantial additional funding to support future operating activities.

Management Comments

• "We are a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine."
• "We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration (FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods."
• "We continue to advance our Preclinical IBD Program, with the goal of having a product candidate ready for an Investigational New Drug (IND Application) with the FDA by December 2026."
• "Our liver predictive power was shown to be 87.5% for a set of challenging liver toxicity cases... The platform identified correctly that 87.5% of the known liver-toxic drugs could be seen as liver toxic using NAMkind liver. This is known as the sensitivity of the platform, which at 87.5% is a worlds best. Importantly, the specificity was 100%, meaning that none of the compounds tested that are not liver toxic were incorrectly identified as having liver toxicity issues by the platform."
• "Based on our current operating plan and available cash resources, we will need substantial additional funding to support future operating activities."
• "We have concluded that the prevailing conditions and ongoing liquidity risks faced by us raise substantial doubt about our ability to continue as a going concern for at least one year following the date these financial statements are issued."

Industry Context

VivoSim Labs is pivoting to capitalize on a growing trend in the pharmaceutical and biotechnology industry towards New Approach Methodologies (NAMs) and 3D human tissue models, driven by regulatory shifts like the FDA's recent announcement favoring non-animal testing. This positions the company in the drug discovery and development services sector, aiming to reduce the high risk and cost associated with bringing therapeutics to market, particularly concerning liver toxicity and intestinal intolerability. The industry is highly competitive, with many established players and academic institutions, but VivoSim's reported 'best-in-class' liver toxicology platform could provide a competitive edge if widely adopted.

Comparison to Industry Standards

• The company's liver toxicology platform demonstrated 87.5% sensitivity and 100% specificity for challenging liver toxicity cases, which it claims is a 'world's best' predictive power for NAMkind liver models. This suggests a strong performance relative to existing methods or competing platforms, though specific comparable companies or projects are not named in the filing.

Corporate Governance

Legal Proceedings

• H.C. Wainwright & Co., LLC filed a complaint against the company on August 27, 2024, alleging breach of a tail financing provision from a May 2023 engagement agreement, seeking compensatory and consequential damages and attorneys fees.
• The company filed an answer to the complaint on October 18, 2024, and is vigorously defending the claims.
• As of June 30, 2025, the company recognized an accrual of $0.6 million for loss contingencies associated with the H.C. Wainwright complaint, with $0.4 million in accrued expenses and $0.2 million as a liability to be settled in equity (warrants).

Related Party Transactions

• Keith Murphy, the company's Executive Chairman, also serves as the Chief Executive Officer and President of Viscient Biosciences, Inc. (Viscient).
• Certain board members (Adam Stern, Douglas Jay Cohen, and David Gobel) are investors in Viscient through convertible promissory notes.
• The company has an Intercompany Agreement with Viscient (dated December 28, 2020) for mutual services related to 3D bioprinting technology, sharing of facilities and equipment, and employee availability.
• For the three months ended June 30, 2025, the company incurred $72,000 in R&D consulting expenses from Viscient.
• The company licenses and cross-licenses certain intellectual property with Viscient.
• On July 25, 2025, the company entered into a letter agreement with SternAegis Ventures through Aegis Capital Corp. (Aegis) for financial advisory services; Adam Stern, a board member, is Head of Private Equity Banking at Aegis and CEO of SternAegis Ventures.

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises and potential adverse impact on share price due to the 'going concern' warning and Nasdaq listing risks.
• Employees may experience continued workforce adjustments, as average R&D and SG&A staff decreased, and there is potential for conflicts of interest regarding the Executive Chairman's time commitment.
• Customers (pharmaceutical and biotech companies) stand to benefit from the company's specialized 3D human tissue testing services, particularly the highly predictive liver toxicology platform.
• Creditors face increased risk due to the company's 'going concern' status and negative cash flows from operations, indicating challenges in meeting future obligations without additional funding.

Next Steps

• Raise substantial additional capital through debt or equity financings, or other financing arrangements.
• Advance the Preclinical IBD Program with the goal of having a product candidate ready for an Investigational New Drug (IND) Application with the FDA by December 2026.
• Continue offering liver toxicology predictive screening and research services to pharmaceutical and biotech companies.
• Seek to establish new strategic partnering, collaboration, and licensing arrangements to support the services platform and R&D efforts.

Key Dates

Recommendation

The explicit 'substantial doubt about its ability to continue as a going concern' is a paramount risk that overrides any operational improvements or strategic pivots. While the company has a promising new business model and positive early data for its liver toxicology platform, its current cash position, increasing cash burn from operations, and the stated need for 'substantial additional funding' indicate a precarious financial situation. The significant dilution risk from future capital raises and the potential for Nasdaq delisting further compound the uncertainty. A seasoned investor would prioritize the fundamental financial viability, which is severely questioned by the going concern warning, making a 'sell' recommendation prudent to mitigate potential further losses.

Keywords

Biotechnology, Pharmaceutical Services, 3D Tissue Models, Liver Toxicology, Inflammatory Bowel Disease, Drug Discovery, Preclinical Development, SEC Filing, 10-Q, Going Concern, Capital Raise, NAM Models, Bioprinting